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Abstract
Persistent Staphylococcus aureus nasal carriers are at high risk of S. aureus infection. The present study delineates a simple strategy aimed
at identifying rapidly and accurately this subset of subjects for clinical or epidemiological purposes. Ninety healthy volunteers were each
identiﬁed as persistent, intermittent or non-nasal carriers of S. aureus by using seven specimens sampled over a 5-week period. By refer-
ence to this so-called reference standard, six other strategies aimed at simplifying and speeding the identiﬁcation of persistent carriers
and based on the qualitative or quantitative detection of S. aureus in one to three nasal samples were evaluated by the measure of the
area under the curve of receiver operating characteristic diagrams. Among strategies using qualitative results, there was no statistical
difference between protocols using seven and three samples. A threshold of 103 CFU of S. aureus per swab was found capable of deﬁn-
ing persistent nasal carriage with a sensitivity of 83.1% and a speciﬁcity of 95.6%. These ﬁgures reached 95.5% and 94.9%, respectively,
by using an algorithm including one or two nasal specimens according to the threshold of 103 CFU of S. aureus in the ﬁrst swab. The
latter two strategies were shown to be costly equivalents. The proposed algorithm-based strategy proved to be relevant to identify
properly and consistently persistent nasal carriers of S. aureus. However, as it was built from data of healthy volunteers, it needs to be
conﬁrmed prospectively on patients potentially at risk for S. aureus infection.
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Introduction
The vestibulum nasi is considered the main site of Staphylo-
coccus aureus colonization in humans (for a recent review
see ref. [1]). Previous studies identiﬁed three patterns includ-
ing persistent, intermittent and non-carrier states in approxi-
mately 20%, 30% and 50% of the whole population,
respectively [1]. Persistent nasal carriers of S. aureus can be
distinguished from intermittent carriers by a lower exchange
rate of S. aureus strains or clones in repeated cultures [2–4]
and by a higher mean number of CFU of S. aureus in the
nose [1,4].
Patients with persistent carriage have been shown to exhi-
bit a higher risk of S. aureus infection than patients with
other statuses [5–7], at least in part by inducing a higher dis-
persion of S. aureus in the environment [1,4,5]. It has been
shown recently that a decolonization procedure using mup-
irocin and chlorhexidine before surgery enabled a signiﬁcant
rate decrease of S. aureus infection [8]. Targeting patients
who would beneﬁt from such a drug-based prevention pro-
tocol could minimize the risk of emergence of S. aureus
resistance [9,10]. Consequently, simple though fully reliable
screening methods are needed to rapidly identify persistent
nasal carriers.
However, the characterization of persistent carriage varies
from one study to another and there is no consensual deﬁni-
tion of the status of S. aureus persistent carrier. In previous
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studies, this status was determined by using from 5 to 12
consecutive specimens taken over several weeks to months
with a positive rate of at least 80% [4,6,11,12]. Seven succes-
sive nasal swab cultures was shown to reliably distinguish
non-carriers from intermittent carriers [1,13]. Only one
study proposed a ‘culture rule’ combining qualitative and
quantitative results from only two nasal swabs taken within a
1-week interval to predict the persistent S. aureus carriage
state with a positive predictive value of 79% [13].
The present study involving healthy volunteers was
designed to simplify the accurate identiﬁcation of S. aureus
persistent carriers. By comparison to a reference protocol
using seven successive specimens, a simpliﬁed algorithm using
quantitative data from one or two nasal swabs in a short inter-
val of time was found to be suitable to accurately segregate
persistent carriers from subjects exhibiting a different status.
Methods
Study population
Ninety-three volunteers from the University Hospital of
Saint-Etienne, France, were included in the study from March
to April 2010. Volunteers were healthy healthcare workers,
aged 18–65 years, and exhibited none of the following exclu-
sion criteria: acute infection, chronic skin disease, current
use of antibiotics and pregnancy. A written informed consent
was obtained from all the volunteers. The study received the
approval of the regional ethical research committee (‘Comite´
de Protection des Personnes Sud-Est I’).
Screening
Seven sampling episodes were scheduled to screen S. aureus
nasal carriage over a 5-week period. During sampling epi-
sodes, nostrils were sampled independently with nylon
ﬂocked swabs (Regular nylon ﬂocked swab 552C, microRhe-
ologics, Brescia, Italy) and rayon swabs (Fastidious anaerobe
swab 108C, Copan, Italy) randomized according to the nos-
tril side [14]. The sampling episodes were scheduled every
2 days for the ﬁrst three specimens (D0, D2, D4) and once
a week for the last four specimens (D7, D15, D23, D31).
Samples were taken by one trained researcher following a
pre-deﬁned protocol; swabs were wetted in physiological
serum, inserted approximately 2 cm into the anterior nostril
and rotated ﬁve times [14].
Microbiological procedures
Samples were processed within 2 h. Swabs were vortexed
for 10 s in 1 mL phosphate-buffered saline and 50 lL of this
solution was plated onto an appropriate chromogenic
medium (BBL CHROMagar Staph aureus, Becton Dickin-
son, Le Pont de Clair, France). Plates were read after 24 h
and 48 h of growth at 36C and pink colonies were plated
onto blood agar for identiﬁcation by matrix-assisted laser
desorption ionization-time of ﬂight mass spectrometry
(MALDI-TOF MS) (Bruker Daltonics, Bremen, Germany)
[15–17]. The bacterial load, expressed as CFU/swab, was
determined by the number of pink colonies after 48 h of
growth on the chromogenic medium. The limit of detection
was 20 CFU/swab of S. aureus and adapted dilutions were
performed to quantify high bacterial loads. As the two nos-
trils were screened independently and in a randomized way,
the highest bacterial load was selected for analysis.
Gentoyping of S. aureus isolates
The strains of S. aureus were characterized by arbitrarily
primed PCR (AP-PCR) using the primers ERIC2 and 1
referred to in ref. [18], as previously described with minor
changes [19]. Brieﬂy, the DNA extraction was performed in
a QIAsymphony machine using a virus/bacteria mini kit
(Qiagen, Courtaboeuf, France). The ampliﬁcation step was
performed in a GeneAmp PCR System 9700 thermocycler
(Applied Biosystems, Villebon-sur-Yvette, France). The ampli-
cons were stained with GelRed (Interchim, Montluc¸on,
France) and separated in a 1.5% agarose gel (UltraPure
Agarose, Invitrogen, Cergy Pontoise, France). The AP-PCR
proﬁles were analysed with QUANTITY ONE Software (Bio-
Rad, Marnes-la-Coquette, France). Strains were considered
different if the proﬁles exhibited more than two bands of dif-
ference with at least one of two primers [19]. The suscepti-
bility of each clone to methicillin was studied by detection of
the mecA gene.
Deﬁnition of nasal carrier state
Assuming that persistent carriers are deﬁned by a positive
rate of nasal swabs of at least 80% [6,11,12,20], persons with
six or seven cultures positive for S. aureus were classiﬁed as
persistent carriers; those with negative results of all cultures
were classiﬁed as non-carriers. All other persons were classi-
ﬁed as intermittent carriers. This strategy was labelled the
‘reference protocol’.
Evaluation of screening strategies of persistent S. aureus
nasal carriage
Based on previously published protocols looking for nasal
carriage of S. aureus [8,13,21–23], six different screening
strategies, lettered from A to F, were evaluated. The ﬁrst
three strategies were based only on qualitative results of
one (A), two (B) or three (C) consecutive positive samples.
Strategies D and E relied on a single sample with a bacterial
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load of >102 and >103 CFU/swab, respectively. Strategy F
was an algorithm combining quantitative results from one or
two nasal samples (see Results section for more details).
Cost evaluation
The cost generated by the different screening strategies was
calculated using the following items: 1.11 € per swab, 1.34 €
per chromogenic medium and 2.44 € per bacterial identiﬁca-
tion by MALDI-TOF MS technology [16].
Statistical analysis
Assuming a prevalence of persistent S. aureus nasal carriers of
24% [11] and a sensitivity of 95% with a precision of 10%, a
number of 73 volunteers was found to be necessary for detect-
ing 18 persistent carriers. The Wilcoxon non-parametric test
was used for mean comparison. Predictive values were cor-
rected by reference to a prevalence of persistent nasal car-
riage of 24% [11], using the Bayes theorem [24]. The SPSS
software (version 16.0, Chicago, IL, USA) was used for statis-
tical analyses and calculation of receiver operating character-
istic (ROC) curves. The area under the curve (AUC) of the
ROC curve of each strategy was compared with that of the
reference protocol and p values were obtained following the
method of Hanley and McNeil [25] using the ROC curve’s
standard error calculated under non-parametric assumption.




From the 93 volunteers incorporated into the study, three
subjects were excluded, respectively, for an antibiotic treat-
ment at D4, a diagnosis of pregnancy at D23, and missing
samples. The analysis was performed on 90 subjects compris-
ing 54 women and 36 men (sex ratio of 0.67) with a mean
age of 36.5 years (range 19.1–62.7).
Nasal carriage
For each volunteer, seven sampling episodes were performed
on a mean period of 31 days (range 25–41). According to
the reference protocol described above, 22 (24.4%) volun-
teers were classiﬁed as persistent carriers, 13 (14.5%) as
TABLE 1. Nasal bacterial loads of Staphylococcus aureus of persistent and intermittent nasal carriers of the studied cohort
Volunteer no.
Nasal S. aureus loads in CFU/swab according to the sequence of sampling episodes (S)
Nasal carriage statusaS1 S2 S3 S4 S5 S6 S7
003 – – 3.8 · 102 1.5 · 104 2.0 · 101 1.1 · 105 1.0 · 107 Intermittent (5/7)
004 – – 2.0 · 101 2.0 · 101 – – – Intermittent (2/7)
007 3.4 · 102 – 2.6 · 102 5.5 · 105 2.9 · 103 2.5 · 103 3.5 · 105 Persistent (6/7)
009 1.6 · 104 1.7 · 104 2.2 · 106 3.4 · 105 1.8 · 104 1.6 · 107 2.6 · 106 Persistent (7/7)
011 2.2 · 103 2.5 · 104 2.3 · 104 1.4 · 105 2.5 · 106 3.5 · 105 2.3 · 103 Persistent (7/7)
014 – – – – – 2.0 · 101 – Intermittent (1/7)
015 2.5 · 103 6.4 · 103 8.0 · 102 1.2 · 104 2.6 · 102 1.7 · 103 3.0 · 102 Persistent (7/7)
018 1.8 · 102 2.1 · 103 1.0 · 102 1.3 · 106 3.1 · 105 2.4 · 106 9.9 · 103 Persistent (7/7)
025 9.5 · 105 1.3 · 104 3.6 · 105 5.0 · 104 1.9 · 106 3.9 · 105 3.7 · 105 Persistent (7/7)
027 – 4.0 · 101 – – – – – Intermittent (1/7)
028 1.0 · 102 – 4.0 · 101 1.4 · 102 – 1.6 · 102 2.0 · 101 Intermittent (5/7)
029 – – – 2.0 · 101 – – – Intermittent (1/7)
034 2.0 · 101 – – – – – – Intermittent (1/7)
036 2.3 · 105 1.3 · 104 6.2 · 105 6.9 · 105 7.5 · 105 1.1 · 104 2.7 · 106 Persistent (7/7)
037 3.8 · 106 3.2 · 104 5.0 · 104 3.6 · 105 6.3 · 106 4.3 · 104 5.5 · 106 Persistent (7/7)
039 – – – – 4.0 · 101 – – Intermittent (1/7)
040 4.0 · 101 4.0 · 101 – 9.4 · 102 – 2.9 · 103 9.0 · 102 Intermittent (5/7)
047 4.2 · 103 9.8 · 105 2.3 · 103 1.1 · 104 2.1 · 105 4.2 · 105 7.3 · 104 Persistent (7/7)
050 5.8 · 106 1.9 · 105 2.2 · 106 1.1 · 107 2.2 · 102 5.0 · 102 2.9 · 106 Persistent (7/7)
051 7.3 · 105 7.0 · 104 2.9 · 106 1.5 · 107 3.9 · 106 6.9 · 107 b Persistent (6/6)
052 1.2 · 102 3.6 · 102 3.8 · 102 – 7.2 · 102 3.4 · 102 6.6 · 102 Persistent (6/7)
058 1.5 · 105 2.9 · 106 6.1 · 105 3.0 · 102 4.1 · 106 4.6 · 107 2.5 · 106 Persistent (7/7)
059 5.7 · 106 8.7 · 105 1.8 · 105 2.2 · 105 3.3 · 106 1.3 · 106 4.8 · 106 Persistent (7/7)
061 1.4 · 106 2.2 · 106 7.2 · 102 1.1 · 103 4.4 · 105 4.5 · 105 9.0 · 105 Persistent (7/7)
067 2.0 · 105 1.2 · 103 1.5 · 106 1.2 · 107 2.6 · 105 2.0 · 101 3.6 · 102 Persistent (7/7)
069 – – 3.2 · 102 – – – – Intermittent (1/7)
070 2.1 · 106 3.1 · 106 1.8 · 105 3.2 · 106 1.4 · 106 3.7 · 106 3.2 · 107 Persistent (7/7)
071 2.8 · 105 1.4 · 108 1.5 · 107 1.5 · 107 2.0 · 105 3.3 · 106 3.1 · 105 Persistent (7/7)
073 – – – – 2.0 · 101 – – Intermittent (1/7)
076 2.0 · 101 – – 2.0 · 101 – – – Intermittent (2/7)
079 2.0 · 103 2.0 · 103 4.0 · 102 4.6 · 102 1.1 · 103 1.2 · 102 2.3 · 103 Persistent (7/7)
080 – – – – 4.2 · 102 – – Intermittent (1/7)
082 3.0 · 105 1.4 · 106 3.6 · 107 8.7 · 104 2.0 · 105 8.1 · 104 3.0 · 104 Persistent (7/7)
087 2.8 · 107 8.0 · 105 1.0 · 106 2.3 · 106 4.7 · 105 3.0 · 104 1.6 · 106 Persistent (7/7)
090 1.8 · 106 2.2 · 106 9.5 · 105 1.0 · 104 2.1 · 106 6.4 · 103 b Persistent (6/6)
aValues in parentheses represent number of positive samples/total samples.
bSamples not performed.
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intermittent carriers and 55 (61.1%) as non-carriers. Table 1
illustrates the quantitative results of S. aureus nasal screening
in persistent and intermittent carriers. The mean of positive
samples per sampling episode was 25.3 (28.1%) with a stan-
dard deviation (SD) of 1.48 (21.6 ± 0.49 and 4.0 ± 1.07 for
persistent and intermittent carriers, respectively). The
amount of S. aureus in nostrils of persistent carriers (median
of 3.03 · 105 CFU/swab) was higher than that in intermittent
carriers (median of 40 CFU/swab) (p <0.001 by Wilcoxon
test) (Fig. 1). All S. aureus isolates (n = 300 from 35 carriers)
were genotyped by AP-PCR; 38 different proﬁles were
obtained according to the criteria described above (data not
shown). A different clone was identiﬁed for at least each
subject, except for a couple of persistent carriers whose
strains exhibited similar proﬁles. Of the 22 persistent carri-
ers, 20 harboured a single clone; in the two remaining cases,
either two or three clones were isolated but a dominant
clone was present in >80% of the samples, which complies
with the above deﬁnition of persistent carriers. None of the
38 clones was found positive for the presence of the mecA
gene.
Screening strategies for identiﬁcation of persistent S. aureus
nasal carriers
Based on qualitative and quantitative data reported in
Table 1 and Fig. 1, different screening strategies aimed to
distinguish between persistent and intermittent carriers were
evaluated by AUC of ROC curves in comparison to the
AUC of the reference protocol. As shown in Table 2, strat-
egy C based on three positive consecutive samples provided
the highest performances among strategies using qualitative
data; the AUC being not statistically different from that of
the reference protocol using seven sampling episodes. When
the data in Table 2 were re-analysed by comparing persistent
carriers with other subjects (including non-carriers and inter-
mittent carriers), all the strategies were found to be not dif-
ferent from the reference protocol, with the exception of
strategy E, which remained less efﬁcient (data not shown).
By combining quantitative results, a new algorithm (strat-
egy F) using one or two sampling episodes was built (Fig. 2):
a carrier was classiﬁed as persistent if the ﬁrst sample recov-
ered >103 CFU/swab or, for counts >102 CFU/swab and
£103 CFU/swab, if the second sample recovered >102 CFU/
swab. As for strategy C, strategy F was shown to exhibit
performances that were not different from that of the refer-
ence protocol (Table 2). Using this algorithm, 92% of the
cohort volunteers were segregated as persistent carrier
(>103 CFU/swab) or non-persistent carrier (£102 CFU/swab)
by using a single sample whereas a second sample was
needed to determine the carriage status of the remaining
volunteers. The costs of the different strategies are shown in
Table 2: the cost of strategy F was very close to that of
strategies using a single swab.
FIG. 1. Comparison of bacterial load according to the nasal carriage
status (p <0.001 by Wilcoxon test).
TABLE 2. Description of different screening strategies proposed to identify Staphylococcus aureus persistent carriers in com-
parison to the reference protocol (consisting of at least six positive out of seven consecutive samples)
No. Screening test Sensitivity, % Speciﬁcity, % PPV, % NPV, % AUC p value* Cost in €a
A 1 positive sample 97.4 (80.5–99.8) 70.3 (40.0–91.1) 52.5 (26.2–77.4) 98.8 (79.7–100) 0.84 (0.68–0.94) 0.01 2.45 (3.14)
B 2 positive consecutive samples 95.5 (77.4–99.8) 88.5 (60.0–98.2) 75.5 (42.2–92.9) 98.3 (83.3–100) 0.92 (0.78–0.98) 0.07 4.90 (6.27)
C 3 positive consecutive samples 93.6 (74.6–99.5) 95.4 (68.5–99.9) 87.8 (50.5–98.5) 97.9 (82.7–100) 0.95 (0.81–0.99) 0.14 7.35 (9.41)
D 1 sample >102 CFU/swab 96.1 (78.4–99.8) 87.9 (59.5–98.0) 75.4 (42.4–91.8) 98.5 (82.5–100) 0.92 (0.78–0.98) 0.05 2.45 (3.14)
E 1 sample >103 CFU/swab 83.1 (61.5–95.2) 95.6 (69.1–99.7) 88.3 (48.3–97.6) 94.6 (78.2–99.6) 0.89 (0.75–0.97) 0.04 2.45 (3.14)
F 1 or 2 quantitative samplesb 95.5 (77.4–99.8) 94.9 (68.1–99.6) 87.7 (51.7–97.6) 98.5 (83.5–100) 0.95 (0.82–0.99) 0.12 2.62 (3.36)
PPV, positive predictive value; NPV, negative predictive value; AUC, area under curve.
Values in parenthesis represent the 95% conﬁdence interval. Data of non-carriers (deﬁned by no positive sample) were excluded of the data analysis.
*p value was calculated by comparison of the AUC value reported in the previous column to the AUC value of the reference protocol (arbitrarily ﬁxed to 1) following the
method of Hanley and McNeil [25].
aValue in parenthesis represents the cost adding identiﬁcation by MALDI-TOF MS technique performed in positive sample (28%).
bThis strategy is detailed in Fig. 2.
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Discussion
Staphylococcus aureus nasal carriage is the main risk factor for
surgical site infection [1,26–29] and among S. aureus nasal
carriers, persistent carriers have the highest risk of infection
with this bacterium [1,6,11]. As recently illustrated [8], pre-
ventive decolonization of S. aureus carriers reduces the risk
of surgical site infection. However, the systematic use of
antibacterial agents to decolonize patients showed a dra-
matic, reciprocal increase of mupirocin [9] or chlorhexidine
[10] resistance. Furthermore, high rates of recolonization
were observed after mupirocin ointment, mainly with the
endogenous strain, suggesting the persistence of S. aureus in
niches potentially associated with persistent carriage status
[1,30–32]. According to the recent reclassiﬁcation of nasal
carriers proposed by van Belkum et al. [11], it might be
worthwhile to reconsider decolonization strategy according
to the actual carriage status. There is an urgent need for
rapid microbiological tools able to segregate accurately per-
sistent nasal carriers of S. aureus from other groups and to
propose a targeted preventive decolonization to patients
with a high risk for S. aureus infection. This study reports a
new algorithm that, in a cohort of healthy volunteers, was
shown able to meet this need by using one or two sampling
episodes together with a quantitative culture method.
Despite the absence of a consensual deﬁnition of nasal
carriage states of S. aureus and assuming that a persistent
carrier could be deﬁned by using seven samples taken during
a 5-week period, the screening of S. aureus nasal carriage
reported in this study exhibited prevalences of 24.4%, 14.5%
and 61.1% for persistent carriers, intermittent carriers and
non-carriers, respectively. These rates are in accordance
with those previously described [1,11], even if the prevalence
of intermittent carriers is lower than expected. The proba-
bility to identify a volunteer as an intermittent carrier
increases with the number of sampling episodes and the
duration of the screening period, as shown by the higher
prevalence of intermittent carriage in studies performed over
a long time [3,6,11,12]. A possible under-estimation of inter-
mittent carriers is not problematic in the present study
because its objective was mainly to distinguish properly per-
sistent carriers from the other subjects. Accordingly, a 5-
week period of screening using seven sampling episodes was
considered sufﬁcient to constitute an accurate reference
standard for testing new strategies aimed at identifying per-
sistent nasal carriers of S. aureus.
The main limitation of this study is the absence of valida-
tion of the algorithm described in Fig. 2 on a cohort of
patients at risk for S. aureus infection, as was performed by
Nouwen et al. [13] for the validation of their ‘culture rule’
using a panel of elderly persons from the Rotterdam cohort.
This step is in progress in our hospital. Another limit of the
study is the fact that the new algorithm requires an excellent
repeatability of the sampling method to quantify properly the
bacterial load. The above results were performed with sam-
ples taken by one researcher trained in the nasal sampling
technique. In routine practice, these samplings are performed
by heterogeneous personnel, which could affect the reliability
of the algorithm. As discussed by Nouwen et al. [13], the
training of healthcare workers to perform sampling methods
is essential to the success of strategies relying on quantitative
microbiological techniques. Moreover, considering the vari-
ability of nasal bacterial loads of S. aureus in different clinical
settings [13,23], the accuracy of the new algorithm should be
veriﬁed prospectively in these speciﬁc populations.
To verify that the population of healthcare workers tested
in this study was not biased in terms of S. aureus nasal car-
riage, we showed that (i) all but two colonized subjects har-
boured non-clonal strains and (ii) subjects deﬁned as
persistent carriers were indeed colonized by the same strain
of S. aureus (even if, for some volunteers, another strain was
also present in a few samples). The latter ﬁnding allows the
exclusion of the misclassiﬁcation of intermittent carriers
FIG. 2. Deﬁnition of the persistent carriage state by the proposed
algorithm in the studied cohort.
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successively colonized by varying clonal lineages by daily con-
tact with infected or colonized patients as persistent carriers.
The absence in our cohort of S. aureus strains resistant to
methicillin provides more evidence that the isolated bacteria
were part of the nasal endogenous ﬂora of the volunteers
and not inherited from nosocomial transmission.
Nevertheless, according to the algorithm, >90% of the vol-
unteers were classiﬁed properly after the ﬁrst nasal sampling
episode. Assuming that these results could be extrapolated to
surgical patients, the patients scheduled for surgery could be
screened at the time of the pre-surgery visit and a minority of
them would need to be sampled again at the anaesthesia visit
or at hospital admission. So, in the majority of cases of planned
surgery, the preventive decolonization could be scheduled and
started before the hospitalization of patients.
To simplify and accelerate the microbiological procedures,
ﬂocked swabs and chromogenic media were used together with
identiﬁcation by MALDI-TOF MS technology. The technique
could still be simpliﬁed by using a nylon ﬂocked swab suspended
in Amies liquid transport medium, which would allow direct
plating of 100 lL transport medium onto the appropriate chro-
mogenic medium without the need for any additional dilution.
Strategies using a real-time PCR assay with [33,34] or
without an integrated extraction step [8,35] are able to
detect the presence of S. aureus colonization within a few
hours. However, it cannot currently help in predicting the
carrier state and is expensive by comparison with standard
culture. In contrast, the strategy proposed in this study is
much cheaper and could provide a result within 24 h, with
an accurate indication of the carrier state in most cases.
In conclusion, an algorithm based on one or two nasal
sampling episodes using ﬂocked nylon swabs coupled to
chromogenic culture was found able to identify properly and
at low cost nasal carriers of S. aureus in a cohort of healthy
volunteers. The following step will comprise the validation of
this algorithm in various clinical settings and under less stan-
dardized sampling and microbiological conditions.
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